Atopic Dermatitis
Featured Article
For the treatment of moderate-to-severe atopic dermatitis, biologics with the most robust efficacy and safety evidence are dupilumab, baricitinib, abrocitinib, and delgocitinib, according to a systematic review.
“Costs likely vary substantially between institutions and practices, but our data suggest that even with an efficient, dedicated prior authorization group, costs are high,” researchers wrote.
An analysis of the characteristics of 308 adults with moderate-to-severe atopic dermatitis starting or switching systematic therapy provides a real-world picture of the substantial burden of the…